SuprefortСупрефорт
A peptide mixture extracted from animal pancreas, studied in institute reports on pancreatitis and digestive enzymes.
What the studies found
Comparison in people · 2013
Suprefort with and without Cerluten and Endoluten in type 2 diabetes
Study of multiple preparations
- Glucose two hours after challenge
- 9.7 ± 0.5 mmol/L with standard care, 7.3 ± 0.6 with added Suprefort, 6.5 ± 0.4 with the three-product combination.Both adjunctive arms are marked significant versus standard care. Exact p values are unavailable.
- Fasting glucose
- 6.8 ± 0.6, 6.1 ± 0.5 and 5.6 ± 0.4 mmol/L, respectively.Both adjunctive arms are marked significant versus standard care.
- Glucose response counts
- Suprefort arm: 195/214 (91.1%) reached the reported upper normal limit by day 18. Three-product arm: 348/375 (92.8%) reportedly normalized by day 12.These outcomes use different assessment days and wording.
The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.
Study notes · methods, sources and limitations
Participants or model 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
Design Moscow, February 2011 to April 2012. Standard treatment alone (329), plus Suprefort (214), or plus Suprefort, Cerluten and Endoluten (375). Suprefort and Cerluten were given orally as two capsules each per day for three months. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified in this source.
- Standard medication dose reportedly reduced
- 0/329 standard care, 114/214 (53.3%) added Suprefort, 279/375 (74.4%) three-product combination.Medication-adjustment criteria and timing are unspecified.
Important limitations
- Allocation, masking, treatment adjustments, exact timing of Table 3 and analysis denominators are unspecified. The response counts use different assessment days. The 918-person Moscow comparison has a different site and design from the 59-person St. Petersburg Medical Center report. Participant-level linkage is unavailable. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
- The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. The reports do not give a systematic harms assessment. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides. · Conference report · company reproduction
Comparison in people · 2006
Suprefort: clinical report on a tissue-derived preparation
- Glucose two hours after challenge, type 2 diabetes subgroup
- 7.0 ± 0.8 mmol/L with Suprefort versus 9.4 ± 0.5 mmol/L with usual care.Table 3 marks p < 0.05 versus usual care.
- Fasting glucose, type 2 diabetes subgroup
- 5.8 ± 0.3 versus 6.6 ± 0.4 mmol/L. Baseline values were 7.9 ± 1.1 and 8.2 ± 0.9 mmol/L respectively.The report marks significance against baseline for each arm.
In the diabetes subgroup, two-hour glucose was 7.0 mmol/L with Suprefort versus 9.4 mmol/L with usual care. Pancreatic enzyme changes in the separate pancreatitis subgroup were reported as trends.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
Design The group table lists 22 treated and 17 controls with type 2 diabetes, and 12 treated and 8 controls with chronic pancreatitis. The diabetes section describes one 10 mg capsule twice daily before meals for 10 days (20 mg/day). The general methods describe one or two 10 mg capsules twice daily for 15 days (20–40 mg/day).
Important limitations
- Random allocation is asserted for the pancreatitis comparison without a method. Changing glucose-lowering co-treatment complicates attribution. This is not evidence for stopping diabetes medication. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
- Group sizes are from Table 1. Allocation methods, changes to other medications and the short follow-up limit attribution.
Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction
About Suprefort
Identity / background source ↗
Research background
Suprefort is a pancreas-derived peptide preparation. A 59-person Medical Center report measured digestive enzymes and blood glucose. A separate Moscow conference report compared three regimens in 918 people with type 2 diabetes.
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
Study methods
Small comparative institute report; allocation, blinding and outcome interpretation require caution
Independent replication
Independent replication not established in this collection
Source access
Report reproduction linked; source language and review scope shown per record
Safety evidence
Short-term reports do not establish long-term safety or equivalence to current products
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2013
Suprefort with and without Cerluten and Endoluten in type 2 diabetes
The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.
Study notes and original source
Suprefort with and without Cerluten and Endoluten in type 2 diabetes
Oral pancreas, brain and pineal polypeptide preparations added to standard therapy · Conference report · company reproduction
D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.
The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.
Results and tables
Reported findings and study design
Moscow, February 2011 to April 2012. Standard treatment alone (329), plus Suprefort (214), or plus Suprefort, Cerluten and Endoluten (375). Suprefort and Cerluten were given orally as two capsules each per day for three months. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified in this source.
Population or model 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glucose two hours after challenge | 9.7 ± 0.5 mmol/L with standard care, 7.3 ± 0.6 with added Suprefort, 6.5 ± 0.4 with the three-product combination. | Both adjunctive arms are marked significant versus standard care. Exact p values are unavailable. |
| Fasting glucose | 6.8 ± 0.6, 6.1 ± 0.5 and 5.6 ± 0.4 mmol/L, respectively. | Both adjunctive arms are marked significant versus standard care. |
| Standard medication dose reportedly reduced | 0/329 standard care, 114/214 (53.3%) added Suprefort, 279/375 (74.4%) three-product combination. | Medication-adjustment criteria and timing are unspecified. |
| Glucose response counts | Suprefort arm: 195/214 (91.1%) reached the reported upper normal limit by day 18. Three-product arm: 348/375 (92.8%) reportedly normalized by day 12. | These outcomes use different assessment days and wording. |
Blood glucose in the three reported groups
| Treatment group | Participants | Fasting before | Fasting after | Two-hour before | Two-hour after |
|---|---|---|---|---|---|
| Standard care | 329 | 8.4 ± 0.6 | 6.8 ± 0.6 | 13.8 ± 0.4 | 9.7 ± 0.5 |
| Standard care + Suprefort | 214 | 8.2 ± 0.7 | 6.1 ± 0.5 | 13.4 ± 0.6 | 7.3 ± 0.6 |
| Standard care + Suprefort, Cerluten and Endoluten | 375 | 8.3 ± 0.7 | 5.6 ± 0.4 | 13.6 ± 0.6 | 6.5 ± 0.4 |
Glucose in mmol/L. Table 3 leaves the timing and the meaning of the ± term unspecified.
The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. The reports do not give a systematic harms assessment. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
- Source reviewed
- Authors’ conference material, Russian reproduction, PDF pages 11–13, methods and Table 3. English and Russian editions describe the same cohort.
Study limitations
- Allocation, masking, treatment adjustments, exact timing of Table 3 and analysis denominators are unspecified. The response counts use different assessment days.
- The 918-person Moscow comparison has a different site and design from the 59-person St. Petersburg Medical Center report. Participant-level linkage is unavailable.
- The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
Reviewed 2026-11-16.
Comparison in people · 2006
Suprefort: clinical report on a tissue-derived preparation
In the diabetes subgroup, two-hour glucose was 7.0 mmol/L with Suprefort versus 9.4 mmol/L with usual care. Pancreatic enzyme changes in the separate pancreatitis subgroup were reported as trends.
Glucose two hours after challenge, type 2 diabetes subgroup · 7.0 ± 0.8 mmol/L with Suprefort versus 9.4 ± 0.5 mmol/L with usual care. · Table 3 marks p < 0.05 versus usual care.
Study notes and original source
Suprefort: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
In the diabetes subgroup, two-hour glucose was 7.0 mmol/L with Suprefort versus 9.4 mmol/L with usual care. Pancreatic enzyme changes in the separate pancreatitis subgroup were reported as trends.
Results and tables
Reported findings and study design
The group table lists 22 treated and 17 controls with type 2 diabetes, and 12 treated and 8 controls with chronic pancreatitis. The diabetes section describes one 10 mg capsule twice daily before meals for 10 days (20 mg/day). The general methods describe one or two 10 mg capsules twice daily for 15 days (20–40 mg/day).
Population or model 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glucose two hours after challenge, type 2 diabetes subgroup | 7.0 ± 0.8 mmol/L with Suprefort versus 9.4 ± 0.5 mmol/L with usual care. | Table 3 marks p < 0.05 versus usual care. |
| Fasting glucose, type 2 diabetes subgroup | 5.8 ± 0.3 versus 6.6 ± 0.4 mmol/L. Baseline values were 7.9 ± 1.1 and 8.2 ± 0.9 mmol/L respectively. | The report marks significance against baseline for each arm. |
Group sizes are from Table 1. Allocation methods, changes to other medications and the short follow-up limit attribution.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
- Source reviewed
- Russian Medical Center report, methods and Tables 1–3, PDF pages 74–76.
Study limitations
- Random allocation is asserted for the pancreatitis comparison without a method. Changing glucose-lowering co-treatment complicates attribution. This is not evidence for stopping diabetes medication.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗